LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 10, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced updated clinical data in patients treated in the Company’s ongoing Phase IIb study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B.
top of page
THE LEADER IN BREAKING BLEEDING DISORDER NEWS
bottom of page